Le Canada aura-t-il les F-35 à temps ?

Sur le même sujet

• 

  28 septembre 2023 | Local, Aérospatial

  Feds should stand up for Canadian aerospace and defence industries with CMMA procurement

  To use a hockey analogy, Boeing plays hard with its elbows up. It does so with the full support of the American government. We need to do the same for our aerospace industry.

• 

  8 avril 2020 | Local, Aérospatial, C4ISR

  CAE answers the federal government’s call to procure ventilators

  The federal government has launched an accelerated procurement plan with several Canadian companies, including Montreal-based CAE, to procure up to 30,000 ventilators. “Canadian companies are answering the call to protect our health care professionals with made-in-Canada solutions,” said Prime Minister Justin Trudeau in a statement on Apr. 7. “This is exactly the kind of innovative, collaborative thinking we need to respond to this rapidly evolving pandemic.” CAE is best known in the aerospace sector for aircraft simulators and training services, helping train over 150,000 pilots per year worldwide. But for more than a decade, the company has also made a name as a healthcare training solutions provider for colleges, universities and hospitals and for medical equipment manufacturers. That includes patient simulators that respond to treatment, including intubation and ventilation. “We have the [medical] and engineering expertise in house – electrical, mechanical, software and human physiology,” said Erick Fortin, director of engineering at CAE Healthcare. A team of 12 engineers took up a challenge issued on Mar. 21 by the Montreal General Hospital Foundation and McGill University Health Centre to develop a simple and low-cost ventilator. Within 10 days, they had a working prototype built with parts from around the lab. “It worked quite well,” said Fortin. “It showed how you can put a team together with the right experts ... and what we can do.” For a company that on Apr. 6 announced the temporary laying off of 2,600 of its 10,500 employees and reduced work weeks for another 900, the opportunity “to do something” has been rewarding. “The whole company is mobilized,” he said. “We are really prepared to produce and we are productizing.” From that initial team of a dozen engineers, the project now has about 100 employees involved. And CAE expects to pull in more as they move to full production. CAE might not be the only company in the Montreal aerospace cluster seeking to solve the ventilator shortage. According to industry think tank Aero Montreal, Pratt & Whitney Canada is also exploring how to use its engineering and manufacturing capabilities to design and validate a ventilator concept that would likely “pull on local manufacturing,” including from Bombardier and AON3D. Fortin said CAE had received “hundreds and hundreds” of emails from companies interested in supplying components, from valves to flow sensors. Though all options are under consideration, including having several contingency plans at the ready, the priority would be to find Canadian suppliers who can deliver high volume. “Some parts are a bit more complex to source, like valves. We'll look at all offers, at all suppliers that can help,” he said. “We are confident that we have everything we need. We certainly have the expertise in house to do the production of thousands of ventilators.” CAE must still fine-tune the prototypes, but it intends to deliver about 10,000 units within three months once it starts production. A low-cost solution might have been part of the engineering team's initial objective, but Fortin admitted the final price might be higher than a typical commercial ventilator. “We try to build it as low as possible,” he said. “As you can imagine, as time is of the essence, cost will be a bit higher that what it could be with a bit more time.” CAE will also be leaning on its training expertise to ensure the final product comes with a complete operator training package. Since mid-March, in fact, the company has been offering online re-skilling courses for ventilators and has released a number of COVID-19 scenarios on its current products such as patient simulators. Fortin noted that more than 2,000 health professionals had participated in coronavirus-related webinars “After 25 years at CAE, I am always surprised at how nimble a big company like this can be, and how we can adjust to different situations,” he said. In its statement on Apr. 7, the government said that about 5,000 Canadian companies have offered expertise and capacity to develop and produce medical personal protective equipment, hand sanitizers and other protective gear. The government is also “working through over 22,000 submissions to Public Services and Procurement Canada from companies interested or able to sell to Canada. All efforts are being made to secure contracts and deliveries as quickly as possible.” “In mobilizing industry and creating partnerships, we are moving swiftly to build up a secure domestic supply of key personal protective equipment to protect Canada's frontline health workers as they fight this pandemic,” said Navdeep Bains, Minister of Innovation, Science and Industry. https://www.skiesmag.com/news/cae-federal-governments-call-procure-ventilators/

• 

  27 mars 2020 | Local, Aérospatial, Naval, Terrestre, C4ISR, Sécurité

  NRC COVID-19 response

  The Government of Canada is taking strong and quick action to protect our economy, and the health and safety of all Canadians during this global outbreak of the novel coronavirus (COVID-19). We are working with our partners as part of the collective effort to help find solutions to the COVID-19 outbreak: 1. The COVID-19 Challenges Procurement Program: NRC Industrial Research Assistance Program and Innovative Solutions Canada Purpose: This program will post challenges seeking near-to-market solutions from small and medium-sized businesses (fewer than 500 staff) that need financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to refine and sell their product or solution to meet a COVID-19 related need. NRC IRAP works with roughly 8,000 small and medium-sized businesses every year through its cross-Canada network of 255 industrial technology advisors and provides over $300 million in support to more than 3,000 technology development projects annually Through this initiative, the Public Health Agency of Canada (PHAC) and Health Canada (HC) will establish a number of challenges corresponding to needs of health providers to deal with COVID-19 NRC IRAP will partner with Innovative Solutions Canada to launch calls for proposals over the next few weeks to address challenges, fund development of solutions, and buy successful products and services needed to address COVID-19 Together, NRC IRAP and Innovative Solutions Canada will: post the PHAC and HC challenges (Innovative Solutions Canada) award Phase 1 funding to successful small and medium-sized businesses to develop a proof of concept for their solution (NRC IRAP) award Phase 2 funding to the firms with the best concepts so they can develop a working prototype (NRC IRAP) The NRC, PHAC, HC or another federal department or agency will then be able purchase the product for use against COVID-19. Innovative Solutions Canada already has challenges in development, which they will begin posting to their website in the coming days. These will continue as PHAC, HC, and health care providers request new topics. Companies with promising technology relevant to the COVID-19 challenges can register their technology or product by clicking on the Register button below. Register 2. The Pandemic Response Challenge Program: National Research Council of Canada Purpose: This program will build teams to address challenges requiring further research and development for solutions to meet COVID-19 related needs. The NRC will build these teams drawing on internal-to-government capacity and academic researchers who register using the button below to indicate their interest, and related areas of expertise and capabilities. The NRC will receive $15M to form dedicated teams to address challenges in the areas of greatest research and development (R&D) need in the fight against COVID-19. The NRC Pandemic Response Challenge Program will accelerate the development of diagnostics and medical countermeasures for a rapid front-line response to protect and treat Canadians. This national vehicle will convene the best Canadian and international researchers from academia and small and medium-sized businesses to collectively accelerate R&D to address specific COVID-19 gaps and challenges as identified by Canadian health experts. The Pandemic Response Challenge Program is currently structured around 3 main research areas: Rapid detection and diagnosis Therapeutics and vaccine development and Digital health. Researchers at Canadian and international universities, government departments, colleges, and highly innovative firms with relevant expertise can now register their interest to work with us on these challenges by clicking the Register button below. Funding is available to help cover the costs of research for academic institutions, small and medium-sized businesses, and other eligible recipients participating in the challenge teams. Over the coming weeks, we will post the specific R&D challenges, send information to registered researchers, and invite them to indicate the expertise and capabilities they can bring to a team. Register 3. Biomanufacturing capacity at Royalmount: NRC Human Health Therapeutics Research Centre Purpose: This initiative will result in a Good Manufacturing Practices platform to develop and scale up COVID-19 Canadian vaccine and therapy candidates. The NRC Biomanufacturing facility, located in the NRC's Royalmount Avenue building in Montréal, is used to develop and scale up processes to produce biological medicines and is managed by the Human Health Therapeutics Research Centre. As part of its development capacity, the facility is equipped with pilot-scale bioreactors (200 L and 500 L), which will be operationally available to produce up to 100,000 doses of vaccine per month within 6 months once a vaccine suitable for front-line responders is available. A $15 million investment will fund the certification of the facility for Good Manufacturing Practices compliance, and will enable production of material that will be used in humans, particularly for vaccines or therapeutics. This certification can also greatly increase the capacity for candidate vaccines or therapeutics to be quickly rolled out and clinically tested, particularly those originating from Canada. The work to refine and certify quality systems at the facility will include: bringing the existing facility to regulatory standards, installing equipment to expand capacity, and managing information. Once certified, this facility will be able to accelerate the scale-up production and testing of various types of vaccine candidates in the context of the current COVID-19 outbreak, including protein-based, viral vector-based, and antibody-based products. https://nrc.canada.ca/en/research-development/research-collaboration/nrc-covid-19-response